IMMUNOTHERAPY

Immunotherapy, Thursday 1 March 2018

08:45

Organiser's Welcome Remarks

08:50

Chair's Opening Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng
09:00

Venture capital funding for the biotech industry: A case study

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important priorities than to invest in early stage companies, the role of the VC becomes even more crucial and necessary for success. Investigate how VC helps biotech to take flight in the competitive generics and biosimilar-focused Asia market.
 
John Connolly
09:20

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
 
Panel discussion
09:40

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
 
Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group
10:20

Speed Networking

10:30

Exhibition Visit & Networking Refreshments

Advanced Therapy Landscape Overview: Where does Asia fit?

Immunotherapy
10:55

Chair's Opening Remarks

Frank Jiang
Immunotherapy
11:00

Cancer precision medicine: From screening to drug selection and development

  • Personalised, affordable and high efficacy are the ideal criteria of a medicine. But the big question is how do we actually move towards providing highly personalised medicine to patients in need?
  • Investigate the pathway to the future of medicine, from drug discovery, development to reaching out to the patients.
Han Chong Toh
Immunotherapy
11:20

Awakening the immune system against cancer - Moving into the clinic

Is cancer immunotherapy the beginning of the end of cancer? Discover cases where immunotherapy can be used to treat complicated cancer cases, including leukaemia, breast cancer and more.
 
Rajiv Rana
Immunotherapy
11:40

Creating immune modulator synergy in cancer management (topic to be confirmed)

Details to be confirmed
Rajiv Rana, Regional Medical Director Asia Pacific, Merck Pte. Ltd.
12:00

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 
Marc Voigt
Immunotherapy
12:00

Topic to be announced

Details to be announced
Marc Voigt, Chief Executive Officer, Prima Biomed Ltd

Table 1: Upcoming vaccines in Asia and how to prepare for it

Table 2: Sustainable vaccines strategies in global health, high-income and private sector

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: What can we learn fromCAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?

Table 6: CRISPR & Precision medicine

Table 7: AI& Big data in drug discovery

Table 8: IoT and blockchain in clinical studies

Table 9: Pricing & Reimbursement strategies in Asia

Table 10: What can we do to reconcile our diversified pharma regulations in Asia?

Table 11: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development

12:50

Exhibition Visit & Networking Lunch

Immuno-oncology

Immunotherapy
14:10

Chair's Opening Remarks

Cristina Chang
Immunotherapy
14:20

Breast cancer vaccines: What have we learnt so far?

  • Addressing the importance of breast cancer vaccines in Asia
  • Exploring unique challenges in Asia and strategies for developing cancer vaccines
  • Case study on OBI pharma
Victor Li
Immunotherapy
14:40

Anti-viral immunotherapy: A case study

Chronic viral infection predisposes a person to the development of cancer. The integrated viral genes in infected cells can be expressed to create viral peptides and presented onto the cell surface. Using our proprietary TCR platform, patient’s T cells can be engineered with high-avidity antiviral TCRs which recognize the tumor-specific viral peptides, leading to the release of cytolytic molecules and the lysis of cancer cells.
Antonio Bertoletti, Co-Founder, Lion TCR
Bandana Sharan
Immunotherapy
15:00

Dendritic cell vaccines in Asia: The first CDSCO approved Indian dendritic cell cancer immunotherapy

Details to be announced
Bandana Sharan, President, Director, Research, APAC Biotech
15:20

Exhibition Visit & Networking Refreshments

Combination Immunotherapy

Junjian Liu
Immunotherapy
16:00

Building the framework of combination immuno-oncology (I-O)

    style="font-size: 10.0pt;">
  •     Overview of current progress, lessons learnt and future prospect of combination I-O
  •     Investigating several combination of checkpoint inhibitors for more effective treatment
  •     Rational vs non rational combinations between checkpoint inhibitors and chemo/radio therapies, which works best?
Junjian Liu, Vice President, Head of Biologics Discovery, Innovent Biologics, Inc
Skye Hung-Chun Cheng
Immunotherapy
16:20

Using genetic information to predict the effectiveness of combination immunotherapy

  • Using molecular analytics in creating effective combinations
  • Disease modelling and prediction with big data and analytics
  • Case study sharing
Skye Hung-Chun Cheng, Chief Scientist, Amwise Diagnostics
Jin San Yoo
Immunotherapy
16:40

Expansions of trials for with Avastin refractory recurrent GBM patients and combination of Tanibirumab + anti-PD1 antibody for refractory cancer patients

  • Insights learnt from Tanibirumab recurrent GBM phase IIa open labelled three arms multi centre trial in Australia 
  • Expansions of trails for with Avastin refractory recurrent GBM patients and combination of Tanibirumab + anti-PD1 antibody for refractory tumours
17:00

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 17/Nov/17 11:05

Immunotherapy, Friday 2 March 2018

09:00

Organiser's Welcome Remarks

09:05

Chair's Opening Remarks

Disruption & Digitalisation

09:10

Pharma 4.0: How digitisation & disruption are creating a need for agility and entrepreneurship in pharma

Digitisation is changing the way pharma interacts with payers, doctors and patients, leading pharma to seek out different skills and personality traits in employees. The challenge is selecting the right disruptor to foster a forward-thinking organisation, and identifying the suitable digital strategy whilst also complying with local regulations and continuing to invest in core R&D capabilities. Hear from big pharma on how they are moving forward and embracing the digital disruption.
 
09:30

CAR-T therapy, the next miracle drug in the making

Recently raised to fame as the new miracle method to treat even the most stubborn cancer cases, CAR-T trials have proven to save patients who have failed all known treatment. However, the rapid advances still stir fears about the safety of the drug after failed cases and deaths on some pharma sponsored trials. With more companies putting their CAR-T pipeline to test in the market, how can regulators ensure patient safety? And from a pharma perspective, what methods can they adopt to produce these highly personalised, customised treatments at scale? Even if it becomes fully approved for commercial deployment, what needs to be done to help patients afford the sky high cost of immunotherapy?
 
Ivor Lim
09:50

Working with increasingly informed and empowered patients in the digital ageEducated guesses, lofty aspirations, hard realities

Ideas are free and to be able to catch one by the wings and bring it back to ground is a wonderful feeling indeed. For doctors, the next step is to bring this good idea into the wards for the patient’s benefit. The transition of bench research to bedside application seems very straightforward at first glance, but it is not until the first steps are taken that one realises the numerous hurdles that have to be surmounted in order to achieve this. In the best interests of the patient, this translational sequence is prescriptive and tedious, and yet it pays no heed to other essentials crucial for the translational effort to be truly successful. This presentation also shares the journey of CellResearch Corporation which 13 years to see the light at the end of the tunnel.
10:10

Exhibition Visit & Networking Refreshments

12:10

Exhibition Visit & Networking Lunch

14:45

Exhibition Visit & Networking Refreshments

Close of Phar-East 2018

last published: 17/Nov/17 11:05